Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Rd Dose-Reduction Algorithm in Elderly/Unfit Newly Diagnosed Multiple Myeloma
2013-004166-33Phase 3Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Fondazione EMN Italy. Primary endpoint: Event-free survival. Started Dec 2013; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-004166-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004166-33.